12.44
-0.64%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Jolly Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300181.SZ. It has been listed since 22 February 2011. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.04bn and net income of CN¥631.9m. At that date it held total assets of CN¥4.71bn and shareholders' equity of CN¥3.18bn.
Zhejiang Jolly Pharmaceutical Co., Ltd. engages in the research & development, production and distribution of pharmaceuticals as well as Chinese herbal medicines. The company is headquartered in Huzhou, Zhejiang. The company went IPO on 2011-02-22. The Company’s main business is mainly involved in pharmaceutical manufacturing, among which the activities are involved in manufacture and sale of active pharmaceutical ingredients, tablets, capsules, granules, Lyophilized powders and other products. The main products include Wuling series, bailing tablets series and Chinese medicine drinking tablets series, among others. Through its subsidiaries, the Company is also engaged in pharmaceutical circulation.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 Feb 2011
- Employees
- 2,455
- Website
- zuoli.com ↗
Leadership
Pay as last reported
- Mr. Youqiang YuChairman of the Board, since 2003CN¥1.0m
- Ms. Li YeChief Financial Officer, Deputy General ManagerCN¥711,600
- Mr. Tao WangGeneral Manager, Director, since 2018CN¥1.1m
- Mr. Guofu FengExecutive Deputy General Manager, Director, since 2017CN¥807,500
- Ms. Yuehong ShenDeputy General Manager, Staff Elected Director, since 2021CN¥743,100
- Ms. Jian ChenDeputy General ManagerCN¥606,700
- Mr. Aihua MaDeputy General ManagerCN¥693,500
- Mr. Xiaoguo PengDeputy General ManagerCN¥711,500
- Ms. Xin TanDeputy General ManagerCN¥721,300
- Ms. Ying WuSecretary of the Board
- Mr. Jianjun WangDirector, since 2014CN¥20,000
- Mr. Xuegen ZhengDirector, since 2008CN¥20,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Jolly Pharmaceutical employs 2,455 full-time employees in Huzhou, China.
- The company produces Wuling series and bailing tablets for pharmaceutical manufacturing.
- Zhejiang Jolly Pharmaceutical has subsidiaries in pharmaceutical circulation.
Weaknesses
- Zhejiang Jolly Pharmaceutical has no mention of international expansion in its business description.
- The company's main products are limited to Wuling series and bailing tablets.
- Zhejiang Jolly Pharmaceutical does not specify new product development plans.
Opportunities
- Zhejiang Jolly Pharmaceutical can leverage its Huzhou headquarters for local market growth.
- The company can expand its product line beyond current Wuling series and bailing tablets.
- Zhejiang Jolly Pharmaceutical may benefit from increasing demand for Chinese herbal medicines.
Threats
- Zhejiang Jolly Pharmaceutical faces competition from other Chinese pharmaceutical companies.
- The company's reliance on traditional Chinese medicine products may limit market reach.
- Zhejiang Jolly Pharmaceutical has no mention of digital transformation strategies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.